Fosrenol is for oral administration.
The tablets must be chewed completely and not swallowed whole. To aid with chewing the tablets may be crushed. Fosrenol oral powder can be used in patients who have difficulty chewing the tablets (see Precautions).
Adults, including elderly (> 65 years): Fosrenol should be taken with or immediately after food, with the daily dose divided between meals. Patients should adhere to recommended diets in order to control phosphate and fluid intake. Fosrenol is presented as a chewable tablet therefore avoiding the need to take additional fluid. Serum phosphate levels should be monitored and the dose of Fosrenol titrated every 2-3 weeks until an acceptable serum phosphate levels is reached, with regular monitoring thereafter.
Control of serum phosphate level has been demonstrated at doses starting from 750 mg per day. The maximum dose studied in clinical trials, in a limited number of patients, is 3750mg. Patients who respond to lanthanum therapy, usually achieve acceptable serum phosphate levels at doses of 1500 - 3000 mg lanthanum per day.
Paediatric population: The safety and efficacy of Fosrenol in children and adolescents below the age of 18 years has not been established (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Hepatic impairment: The effect of hepatic impairment on Fosrenol pharmacokinetics has not been assessed. Due to its mechanism of action and the lack of liver metabolism doses in hepatic impairment should not be modified, but patients should be monitored carefully (see Precautions and Pharmacology: Pharmacokinetics under Actions).